These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
483 related articles for article (PubMed ID: 34748194)
1. Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients. Zhao YC; Zou Y; Xiao YW; Wang F; Zhang BK; Xiang DX; Yu F; Luo H; Sandaradura I; Yan M Infect Dis Ther; 2022 Feb; 11(1):201-216. PubMed ID: 34748194 [TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics/Pharmacodynamics and Clinical Outcomes of Meropenem in Critically Ill Patients. Boonpeng A; Jaruratanasirikul S; Jullangkoon M; Samaeng M; Wattanavijitkul T; Bhurayanontachai R; Pattharachayakul S Antimicrob Agents Chemother; 2022 Nov; 66(11):e0084522. PubMed ID: 36226944 [TBL] [Abstract][Full Text] [Related]
3. Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization. Cojutti PG; Gatti M; Rinaldi M; Tonetti T; Laici C; Mega C; Siniscalchi A; Giannella M; Viale P; Pea F Front Pharmacol; 2021; 12():781892. PubMed ID: 34955851 [No Abstract] [Full Text] [Related]
4. Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection. Lan J; Wu Z; Wang X; Wang Y; Yao F; Zhao BX; Wang Y; Chen J; Chen C J Pharm Sci; 2022 Jun; 111(6):1833-1842. PubMed ID: 35090867 [TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children. Cies JJ; Moore WS; Enache A; Chopra A J Pediatr Pharmacol Ther; 2017; 22(4):276-285. PubMed ID: 28943823 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation. Lee JH; Lee DH; Kim JS; Jung WB; Heo W; Kim YK; Kim SH; No TH; Jo KM; Ko J; Lee HY; Jun KR; Choi HS; Jang JH; Jang HJ Front Pharmacol; 2021; 12():768912. PubMed ID: 34790131 [No Abstract] [Full Text] [Related]
7. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy. Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189 [TBL] [Abstract][Full Text] [Related]
8. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients. Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344 [TBL] [Abstract][Full Text] [Related]
9. Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients. Truong AQ; Dao XC; Vu DH; Nguyen HA; Do THG; Tran NT; Tran NM; Vu NB; Pham HN; Bui VC; Trinh TA; Dang QT; Nguyen GB; Lipman J; Cotta MO; Roberts JA Antimicrob Agents Chemother; 2022 Nov; 66(11):e0032122. PubMed ID: 36197095 [TBL] [Abstract][Full Text] [Related]
10. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis. Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669 [TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation. O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127 [TBL] [Abstract][Full Text] [Related]
13. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study. Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601 [TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation. Lee DH; Kim HS; Park S; Kim HI; Lee SH; Kim YK Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834278 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation. Idoate Grijalba AI; Aldaz Pastor A; Marquet P; Woillard JB Eur J Clin Pharmacol; 2019 Oct; 75(10):1405-1414. PubMed ID: 31338539 [TBL] [Abstract][Full Text] [Related]
17. Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients. Gan Y; Meng X; Lei N; Yu H; Zeng Q; Huang Q Infect Drug Resist; 2023; 16():3989-3997. PubMed ID: 37366501 [TBL] [Abstract][Full Text] [Related]
18. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients. Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665 [TBL] [Abstract][Full Text] [Related]
19. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005 [TBL] [Abstract][Full Text] [Related]
20. Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis. Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA Int J Antimicrob Agents; 2016 Nov; 48(5):542-546. PubMed ID: 27771187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]